Greg D. Carmichael Acquires 2,000 Shares of Encompass Health Co. (NYSE:EHC) Stock

Encompass Health Co. (NYSE:EHC - Get Free Report) Director Greg D. Carmichael purchased 2,000 shares of Encompass Health stock in a transaction on Friday, May 3rd. The shares were acquired at an average cost of $83.73 per share, for a total transaction of $167,460.00. Following the purchase, the director now owns 17,050 shares in the company, valued at $1,427,596.50. The acquisition was disclosed in a document filed with the SEC, which is available through this link.

Encompass Health Stock Up 1.7 %

NYSE:EHC traded up $1.42 during mid-day trading on Tuesday, reaching $85.93. The stock had a trading volume of 973,785 shares, compared to its average volume of 668,731. The company has a debt-to-equity ratio of 1.14, a current ratio of 1.37 and a quick ratio of 1.37. The stock's 50 day simple moving average is $79.33 and its two-hundred day simple moving average is $71.79. Encompass Health Co. has a 1-year low of $57.55 and a 1-year high of $86.60. The company has a market capitalization of $8.65 billion, a price-to-earnings ratio of 23.22, a price-to-earnings-growth ratio of 1.30 and a beta of 0.92.

Encompass Health (NYSE:EHC - Get Free Report) last issued its earnings results on Wednesday, April 24th. The company reported $1.12 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.93 by $0.19. Encompass Health had a net margin of 7.60% and a return on equity of 18.01%. The firm had revenue of $1.32 billion for the quarter, compared to analysts' expectations of $1.27 billion. During the same quarter last year, the company posted $0.88 earnings per share. Encompass Health's revenue was up 13.4% on a year-over-year basis. Equities analysts anticipate that Encompass Health Co. will post 4.1 EPS for the current year.

Encompass Health Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, July 15th. Stockholders of record on Monday, July 1st will be issued a dividend of $0.15 per share. The ex-dividend date of this dividend is Friday, June 28th. This represents a $0.60 dividend on an annualized basis and a dividend yield of 0.70%. Encompass Health's dividend payout ratio (DPR) is presently 16.22%.

Institutional Investors Weigh In On Encompass Health

Hedge funds have recently made changes to their positions in the business. Principal Securities Inc. acquired a new position in shares of Encompass Health during the fourth quarter valued at approximately $25,000. Benjamin F. Edwards & Company Inc. grew its position in Encompass Health by 360.2% in the fourth quarter. Benjamin F. Edwards & Company Inc. now owns 405 shares of the company's stock worth $27,000 after buying an additional 317 shares during the last quarter. McGlone Suttner Wealth Management Inc. acquired a new position in Encompass Health in the fourth quarter worth approximately $30,000. GAMMA Investing LLC purchased a new position in Encompass Health during the 4th quarter worth approximately $33,000. Finally, C M Bidwell & Associates Ltd. purchased a new position in Encompass Health during the 3rd quarter worth approximately $35,000. Institutional investors own 97.25% of the company's stock.

Analyst Ratings Changes

A number of research analysts have weighed in on the company. Raymond James reissued a "strong-buy" rating and set a $95.00 price target (up previously from $85.00) on shares of Encompass Health in a research note on Friday, April 26th. Mizuho increased their target price on Encompass Health from $93.00 to $95.00 and gave the stock a "buy" rating in a research report on Thursday, April 25th. Truist Financial increased their target price on Encompass Health from $82.00 to $86.00 and gave the stock a "buy" rating in a research report on Friday, February 9th. Barclays increased their target price on Encompass Health from $101.00 to $108.00 and gave the stock an "overweight" rating in a research report on Thursday, April 25th. Finally, William Blair reaffirmed an "outperform" rating on shares of Encompass Health in a research report on Wednesday, February 7th. Eight research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat.com, Encompass Health presently has a consensus rating of "Buy" and an average target price of $90.29.

Encompass Health Company Profile

Encompass Health Corporation provides post-acute healthcare services in the United States and Puerto Rico. It owns and operates inpatient rehabilitation hospitals that provide medical, nursing, therapy, and ancillary services. The company provides specialized rehabilitative treatment on an inpatient basis to patients who have experienced physical or cognitive disabilities or injuries due to medical conditions, such as strokes, hip fractures, and various debilitating neurological conditions.